Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.

Targeted oncology - 1 Feb 2016

Kramkimel N, Thomas-Schoemann A, Sakji L, Golmard Jl, Noe G, Regnier-Rosencher E, Chapuis N, Maubec E, Vidal M, Avril Mf, Goldwasser F, Mortier L, Dupin N, Blanchet B

Abstract excerpt

Vemurafenib is a BRAF kinase inhibitor approved for first-line treatment of metastatic BRAF (V600) -mutant melanoma. However, data on the pharmacokinetic/pharmacodynamic (PK/PD) relationship are lacking. The aim of this prospective, multicenter study was to explore the PK/PD relationship for vemurafenib in outpatients with advanced BRAF-mutated melanoma. Fifty-nine patients treated with single-agent vemurafenib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Tissue Distribution

Share to Vemurafenib

Source

Identifiers

PMID: 26208946
DOI: 10.1007/s11523-015-0375-8

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Vemurafenib pharmacokinetics and its correlation with efficacy and safety in outpatients with advanced BRAF-mutated melanoma.PMID 26208946Read ↗

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.Semantic proximity Read ↗

Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAFV600 mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysis.Semantic proximity Read ↗

Vemurafenib in Chinese patients with BRAFV600 mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.Semantic proximity Read ↗

Efficacy of Vemurafenib Treatment in 43 Metastatic Melanoma Patients with BRAF Mutation. Single-Institute Retrospective Analysis, Early Real-Life Survival Data.Semantic proximity Read ↗

Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.Semantic proximity Read ↗

Vemurafenib. Value unclear in metastatic melanoma.Semantic proximity Read ↗

Improved survival with vemurafenib in melanoma with BRAF V600E mutation.Semantic proximity Read ↗

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib.Semantic proximity Read ↗

The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.Semantic proximity Read ↗

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.Semantic proximity Read ↗

Clinical Pharmacokinetics of Vemurafenib in BRAF-Mutated Melanoma Patients.Semantic proximity Read ↗

The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.